Last reviewed · How we verify
ETVAX
At a glance
| Generic name | ETVAX |
|---|---|
| Sponsor | PATH |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase 2 Bridging Study to Assess the New Formulation of ETVAX (PHASE2)
- Prevention of Diarrheal Disease Due to Infection With Enterotoxigenic E. Coli (ETEC) (PHASE2)
- Enterotoxigenic Escherichia Coli (ETEC) ETVAX Vaccine Trial in Bangladesh (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ETVAX CI brief — competitive landscape report
- ETVAX updates RSS · CI watch RSS
- PATH portfolio CI